Lizy Windsor
Psychiatric/Mental Health · Glendale, AZNPI 1912514878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,544, 2.7 times the $929 reported in 2021. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$689
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$605
- Alkermes, Inc.$595
- Johnson & Johnson$534
- Teva Pharmaceuticals USA, Inc.$453
- plus $3K from 22 others
What the payments were for
- Food & beverage$7,74299%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,574 |
| Otsuka America Pharmaceutical, Inc. | 42 | $689 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $605 |
| Alkermes, Inc. | 29 | $595 |
| Johnson & Johnson | 21 | $534 |
| Teva Pharmaceuticals USA, Inc. | 30 | $453 |
| Almatica Pharma LLC | 20 | $402 |
| Vanda Pharmaceuticals Inc. | 13 | $359 |
| Lundbeck LLC | 17 | $310 |
| Neurocrine Biosciences, Inc. | 14 | $290 |
| Bausch Health US, LLC | 15 | $271 |
| E.r. Squibb & Sons, L.L.C. | 15 | $268 |
| Indivior Inc. | 9 | $259 |
| Supernus Pharmaceuticals, Inc. | 12 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Corium, LLC | 6 | $129 |
| Janssen Scientific Affairs, LLC | 1 | $117 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Tris Pharma Inc | 4 | $88 |
| Avanir Pharmaceuticals, Inc. | 5 | $77 |
| Merck | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 6 | $63 |
| Eisai Inc. | 3 | $48 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Alfasigma USA, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $19 |
| Braeburn Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$117
How this compares
$7,789 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $100,425 |
| SpravatoEsketamine Hcl | 74 | $86,445 |
| RexultiBrexpiprazole | 31 | $47,896 |
| VraylarCariprazine Hcl | 29 | $42,756 |
| AplenzinBupropion Hbr | 14 | $41,186 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $8,471 |
| CymbaltaDuloxetine Hcl | 13 | $7,555 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,765 |
| Loreev XrLorazepam | 12 | $5,259 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 92 | $4,427 |
| Aripiprazole | 132 | $4,266 |
| Quetiapine Fumarate | 183 | $2,787 |
| Lamotrigine | 184 | $2,211 |
| Lurasidone Hcl | 65 | $2,011 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 144 | $1,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $453 | $100,42513 claims |
| Johnson & JohnsonSpravato | $534 | $86,44574 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $689 | $47,89631 claims |
| AbbVieVraylar | $1,574 | $42,75629 claims |
| Bausch Health US, LLCAplenzin | $271 | $41,18614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $132 | $15,23637 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $402 | $6,01585 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Glendale
- Barbara KayiiraGlendale$10K
- Curtis AndrewsGlendale$9K
- Lydia VerattiGlendale$9K
- Sarbjit SinghGlendale$6K
- Elizabeth ElliottPhoenix$363K
- Diane StrickerGilbert$281K
- Russell HorningPhoenix$254K
- Stacy UnderwoodMesa$252K
- Brett LeifsonScottsdale$90K
- Claire ReecePhoenix$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.